Sangamo Therapeutics, Inc. (0R1D.L)

USD 0.57

(-11.67%)

Inventory Summary of Sangamo Therapeutics, Inc.

  • Sangamo Therapeutics, Inc.'s latest annual inventory in 2023 was - USD , down -100.0% from previous year.
  • Sangamo Therapeutics, Inc.'s latest quarterly inventory in 2024 Q2 was - USD , down -100.0% from previous quarter.
  • Sangamo Therapeutics, Inc. reported annual inventory of 1.00 USD in 2022, up 100.0% from previous year.
  • Sangamo Therapeutics, Inc. reported annual inventory of -88.16 Million USD in 2021, down -74.49% from previous year.
  • Sangamo Therapeutics, Inc. reported quarterly inventory of 1.00 USD for 2024 Q1, down 0.0% from previous quarter.
  • Sangamo Therapeutics, Inc. reported quarterly inventory of - USD for 2023 Q2, down 0.0% from previous quarter.

Annual Inventory Chart of Sangamo Therapeutics, Inc. (2023 - 1996)

Historical Annual Inventory of Sangamo Therapeutics, Inc. (2023 - 1996)

Year Inventory Inventory Growth
2023 - USD -100.0%
2022 1.00 USD 100.0%
2021 -88.16 Million USD -74.49%
2020 -50.53 Million USD -124.44%
2019 -22.51 Million USD -5903.73%
2018 -375 Thousand USD 70.05%
2017 -1.25 Million USD -458.93%
2016 -224 Thousand USD 27.04%
2015 -307 Thousand USD 99.34%
2014 -46.74 Million USD -22.28%
2013 -38.22 Million USD -206.33%
2012 -12.47 Million USD 0.0%
2011 - USD 0.0%
2010 - USD 0.0%
2009 - USD 0.0%
2008 - USD 0.0%
2007 - USD 0.0%
2006 - USD 0.0%
2005 - USD 0.0%
2004 - USD 0.0%
2003 - USD 0.0%
2002 - USD 0.0%
2001 - USD 0.0%
2000 - USD 0.0%
1999 - USD 0.0%
1998 - USD 0.0%
1997 - USD 0.0%
1996 - USD 0.0%

Peer Inventory Comparison of Sangamo Therapeutics, Inc.

Name Inventory Inventory Difference
uniQure N.V. 12.02 Million USD 100.0%
Agios Pharmaceuticals, Inc. 19.07 Million USD 100.0%
Amicus Therapeutics, Inc. 59.69 Million USD 100.0%
Atara Biotherapeutics, Inc. 9.7 Million USD 100.0%
bluebird bio, Inc. 22.91 Million USD 100.0%
Cara Therapeutics, Inc. 2.82 Million USD 100.0%
Imunon, Inc. - USD NaN%
Editas Medicine, Inc. - USD NaN%
IQVIA Holdings Inc. - USD NaN%
Mettler-Toledo International Inc. 385.86 Million USD 100.0%
Myriad Genetics, Inc. 20.1 Million USD 100.0%
Neurocrine Biosciences, Inc. 38.3 Million USD 100.0%
Supernus Pharmaceuticals, Inc. 77.4 Million USD 100.0%
Verastem, Inc. - USD NaN%
Walgreens Boots Alliance, Inc. 8.32 Billion USD 100.0%
Waters Corporation 516.23 Million USD 100.0%
Thermo Fisher Scientific Inc. 5.08 Billion USD 100.0%
Biogen Inc. 2.52 Billion USD 100.0%
Nektar Therapeutics 16.1 Million USD 100.0%
Perrigo Company plc 1.14 Billion USD 100.0%
Dynavax Technologies Corporation 53.29 Million USD 100.0%
Illumina, Inc. 587 Million USD 100.0%
Corbus Pharmaceuticals Holdings, Inc. - USD NaN%
Iovance Biotherapeutics, Inc. 10.37 Million USD 100.0%
Heron Therapeutics, Inc. 42.11 Million USD 100.0%
Unity Biotechnology, Inc. - USD NaN%
BioMarin Pharmaceutical Inc. 1.1 Billion USD 100.0%
Evolus, Inc. 10.99 Million USD 100.0%
Adicet Bio, Inc. - USD NaN%
Aclaris Therapeutics, Inc. - USD NaN%
Regeneron Pharmaceuticals, Inc. 2.58 Billion USD 100.0%
Esperion Therapeutics, Inc. 65.62 Million USD 100.0%
FibroGen, Inc. 41.56 Million USD 100.0%
Agilent Technologies, Inc. 1.03 Billion USD 100.0%
OPKO Health, Inc. 65.69 Million USD 100.0%
Homology Medicines, Inc. - USD NaN%
Geron Corporation - USD NaN%
Alnylam Pharmaceuticals, Inc. 89.14 Million USD 100.0%
Exelixis, Inc. 17.32 Million USD 100.0%
Viking Therapeutics, Inc. - USD NaN%
Anavex Life Sciences Corp. - USD NaN%
Intellia Therapeutics, Inc. - USD NaN%
Zoetis Inc. 2.56 Billion USD 100.0%
Axsome Therapeutics, Inc. 15.13 Million USD 100.0%
Abeona Therapeutics Inc. -2.44 Million USD 100.0%
Vertex Pharmaceuticals Incorporated 738.8 Million USD 100.0%
Kala Pharmaceuticals, Inc. - USD NaN%
Ionis Pharmaceuticals, Inc. 28.42 Million USD 100.0%
Sarepta Therapeutics, Inc. 322.85 Million USD 100.0%
Corcept Therapeutics Incorporated 7.73 Million USD 100.0%
Halozyme Therapeutics, Inc. 127.6 Million USD 100.0%
Blueprint Medicines Corporation 21.22 Million USD 100.0%
Insmed Incorporated 83.24 Million USD 100.0%
TG Therapeutics, Inc. 39.82 Million USD 100.0%
Incyte Corporation 62.97 Million USD 100.0%
Emergent BioSolutions Inc. 328.9 Million USD 100.0%